LTRNHIGH SIGNALFINANCIAL10-K

LTRN experienced severe balance sheet deterioration with stockholders' equity plummeting 69% and total assets declining 57%, while simultaneously launching a new AI platform and expanding clinical trials.

The massive decline in stockholders' equity from $21.2M to $6.5M combined with substantial asset shrinkage indicates potential dilutive financing or significant write-downs that materially weakened the company's financial position. Despite improved operating performance, the balance sheet deterioration raises concerns about financial sustainability and the company's ability to fund its expanded clinical pipeline and new AI platform development.

Comparing 2026-03-30 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

LTRN shows a mixed financial picture with operational improvements overshadowed by severe balance sheet weakness. While operating cash flow improved 12% and net losses narrowed 17.6% alongside reduced R&D spending, the company's financial foundation deteriorated dramatically with stockholders' equity falling 69% and total assets declining 57%. The 41% drop in cash combined with the massive equity decline suggests either significant dilutive financing or substantial asset impairments, creating serious questions about the company's financial stability despite operational progress.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-86.4%
$13K→$2K

Capex reduced 86.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Share Buybacks
Cash Flow
-79.9%
$2.5M→$500K

Buyback activity reduced 79.9% — capital being redeployed elsewhere or cash conservation underway.

Stockholders Equity
Balance Sheet
-69.2%
$21.2M→$6.5M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
-57.2%
$25.2M→$10.8M

Current assets declined 57.2% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-56.8%
$25.6M→$11.0M

Total assets contracted 56.8% — asset sales, write-downs, or balance sheet optimization underway.

Cash & Equivalents
Balance Sheet
-41.1%
$7.5M→$4.4M

Cash declined 41.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

R&D Expense
P&L
-28.6%
$16.1M→$11.5M

R&D spending cut 28.6% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+19.1%
-$22.2M→-$18.0M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+17.6%
-$20.8M→-$17.1M

Net income grew 17.6% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
+12%
-$17.8M→-$15.7M

Operating cash flow grew 12% — strong conversion of earnings to cash, healthy business fundamentals.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-27
ADDED
As of March 13, 2026, the registrant had 11,254,697 shares of common stock, $ 0.0001 par value per share outstanding.
On average, our newly developed drug programs have been advanced from initial A.I.
insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-$2.5 million per program.
In January 2026, we introduced withZeta.ai a generative AI platform purpose-built to empower researchers and clinicians to accelerate rare cancer research and drug development, dramatically improve research quality, and reduce R D costs.
withZeta s multi-agentic architecture combines intelligent orchestration using a combination of proprietary knowledge bases and publicly available data with autonomous task completion to deliver a true co-scientist experience one that brings the collective insight of thousands of domain experts, millions of publications, and billions of data points to address some of oncology s most difficult challenges and disease subtypes.
+7 more — sign up free →
REMOVED
As of March 17, 2025, the registrant had 10,784,725 shares of common stock, $ 0.0001 par value per share outstanding.
Our strategy is to both develop new drug candidates using our RADR platform and other machine learning driven methodologies, and to pursue the development of drug candidates that have undergone previous clinical trial testing or that may have been halted in development or deprioritized because of insufficient clinical trial efficacy (i.e., a meaningful treatment benefit relevant for the disease or condition under study as measured against the comparator treatment used in the relevant clinical testing) or for strategic reasons by the owner or development team responsible for the compound.
Additionally, these drug candidates may also have a body of existing data supporting the potential mechanism(s) by which they achieve their intended biologic effect, but often require more targeted trials in a stratified group of patients to demonstrate statistically meaningful results.
In this context, we intend to create a diverse portfolio of oncology drug candidates for further development towards regulatory and marketing approval with the objective of establishing a leading A.I.-driven, methodology for treating the right patient with the right oncology therapy.
We believe the combination of our therapeutic area expertise, our A.I.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →